Skip to content
Research Article Open access CC BY 3.0

A Comparison of the Humoral Immune Response Induced by a Recombinant Human Protein in Wild Type Mice and in Transgenic Mice Expressing the Protein

Britta Granath, Jan Holgersson, Karin Cederbrant, Ann Lövgren, Nina Brenden

Journal of Pharmaceutical Research International · pp. 2511–2524 · Published 5 Nov 2014

10.9734/BJPR/2014/10923

Abstract

Aim: The aim of this work was to investigate the correlation between anti drug antibody (ADA) induction and how different manufacturing processes of biopharmaceuticals affect the immunogenicity of the protein. This was done by testing four different batches of the same recombinant human protein in transgenic (Tg) mice. Methodology: Wild type (Wt) and human protein-transgenic (Tg) mice were challenged by repeated subcutaneous injections of four batches of a drug candidate protein, obtained by different purification methods. Differences between drug-specific IgG1, IgG2a, IgG2b, IgG3 and IgM antibody patterns produced in Tg vs. Wt mice were investigated and compared to the plasma cytokine profiles. A conventional ELISA was used as a reference method for ADA detection. Results: ADA responses detected in Tg mice were mainly of the IgG1 subclass and occurred only in significant response to the batch containing the highest level of proteins originating from the recombinant host cells. Wt mice, on the other hand, showed a combined IgG1/IgG2b response to all drug batches, except to the batch with the highest purity. The most pure batch failed to induce significant ADA in both Wt and Tg animals, suggesting host cell derived impurities to be a strong contributing factor to the antibody responses observed. Conclusion: Thus, an isolated IgG1 response in drug-tolerant Tg mice may serve as a potential biomarker of an immunological reaction to process-related impurities of the protein drug. In contrast, a combined IgG1/IgG2b-profile, as observed in immunoreactive Wt mice, more likely reflects a xeno-response.

ADA biopharmaceuticals manufacturing process tg mice Ig subclasses cytokine profile batch variation

References (28)

  1. 1 Protein therapeutics: a summary and pharmacological classification [DOI]
  2. 2 Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products [DOI]
  3. 3 Immunogenicity of therapeutic proteins: Clinical implications and future prospects [DOI]
  4. 4 Factors influencing the immunogenicity of therapeutic proteins [DOI]
  5. 5 Immunological mechanism underlying the immune response to recombinant human protein therapeutics [DOI]
  6. 6 Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics [DOI]
  7. 7 Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients [DOI]
  8. 8 Immunogenicity of Therapeutic Proteins: The Use of Animal Models [DOI]
  9. 9 Taking immunogenicity assessment of therapeutic proteins to the next level [DOI]
  10. 10 Oxidized and Aggregated Recombinant Human Interferon Beta is Immunogenic in Human Interferon Beta Transgenic Mice [DOI]
  11. 11 Immunogenicity and other problems associated with the use of biopharmaceuticals [DOI]
  12. 12 Alternative Strategies for Toxicity Testing of Species-Specific Biopharmaceuticals [DOI]
  13. 13 The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics [DOI]
  14. 14 Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria [DOI]
  15. 15 Characterization of Antibodies Induced by Human Factor VIII in a Murine Knockout Model of Hemophilia A [DOI]
  16. 16 Immunogenicity of Recombinant Human Interferon Beta Interacting with Particles of Glass, Metal, and Polystyrene [DOI]
  17. 17 Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics [DOI]
  18. 18 Adverse drug reactions to biologics [DOI]
  19. 19 Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta [DOI]
  20. 20 Selective increases in antibody isotypes and immunoglobulin G subclass responses to secreted antigens in tuberculosis patients and healthy household contacts of the patients [DOI]
  21. 21 A Cellular Viewpoint of Anti-FVIII Immune Response in Hemophilia A [DOI]
  22. 22 Strategies for preclinical immunogenicity assessment of protein therapeutics.
  23. 23 Antibody Response Against Betaferon® in Immune Tolerant Mice: Involvement of Marginal Zone B-cells and CD4+ T-cells and Apparent Lack of Immunological Memory [DOI]
  24. 24 Mechanism of the Immune Response to Human Factor VIII in Murine Hemophilia A [DOI]
  25. 25 Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testing [DOI]
  26. 26 Isotype and IgG Subclass Distribution of Autoantibody Response to Alpha-enolase Protein in Adult Patients with Severe Asthma [DOI]
  27. 27 Studies on the immunogenicity of hCEA in a transgenic mouse model [DOI]
  28. 28 Refined analysis of antigen-specific antibody responses – A new one-step tool in immunogenicity studies [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

6

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.